| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Squamous Cell | 40 | 2024 | 5437 | 2.350 |
Why?
|
| Mouth Neoplasms | 13 | 2023 | 713 | 2.290 |
Why?
|
| Head and Neck Neoplasms | 35 | 2024 | 3976 | 1.790 |
Why?
|
| Tumor Suppressor Protein p53 | 23 | 2024 | 3552 | 1.200 |
Why?
|
| Papillomavirus Infections | 12 | 2024 | 980 | 1.120 |
Why?
|
| Mutation | 28 | 2023 | 15179 | 0.950 |
Why?
|
| Caspase 8 | 4 | 2020 | 145 | 0.940 |
Why?
|
| Tongue Neoplasms | 4 | 2022 | 246 | 0.810 |
Why?
|
| Mouth | 1 | 2018 | 122 | 0.580 |
Why?
|
| DNA Methylation | 5 | 2018 | 2669 | 0.580 |
Why?
|
| F-Box Proteins | 2 | 2013 | 96 | 0.520 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2015 | 80 | 0.520 |
Why?
|
| DNA Copy Number Variations | 4 | 2015 | 1516 | 0.510 |
Why?
|
| Promoter Regions, Genetic | 4 | 2020 | 3101 | 0.510 |
Why?
|
| Precancerous Conditions | 6 | 2022 | 1058 | 0.500 |
Why?
|
| Papillomaviridae | 9 | 2022 | 624 | 0.480 |
Why?
|
| Cell Line, Tumor | 29 | 2024 | 14551 | 0.470 |
Why?
|
| Nitrophenols | 1 | 2013 | 92 | 0.440 |
Why?
|
| Maxillary Sinus Neoplasms | 3 | 2019 | 117 | 0.430 |
Why?
|
| Cell Cycle Proteins | 6 | 2022 | 2045 | 0.430 |
Why?
|
| Ubiquitin-Protein Ligases | 3 | 2022 | 854 | 0.410 |
Why?
|
| Biphenyl Compounds | 1 | 2013 | 194 | 0.410 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2013 | 275 | 0.410 |
Why?
|
| Radiation Tolerance | 5 | 2021 | 629 | 0.400 |
Why?
|
| Alphapapillomavirus | 3 | 2022 | 171 | 0.390 |
Why?
|
| Histone Deacetylases | 1 | 2013 | 365 | 0.380 |
Why?
|
| Receptors, Opioid, mu | 2 | 2021 | 86 | 0.380 |
Why?
|
| Receptor, Notch1 | 6 | 2019 | 218 | 0.370 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2017 | 612 | 0.360 |
Why?
|
| Clinical Medicine | 1 | 2009 | 24 | 0.340 |
Why?
|
| Research Personnel | 1 | 2009 | 156 | 0.310 |
Why?
|
| Humans | 76 | 2024 | 261506 | 0.310 |
Why?
|
| Gene Expression Regulation, Neoplastic | 10 | 2021 | 8873 | 0.300 |
Why?
|
| Smoking | 3 | 2020 | 2440 | 0.290 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2013 | 1493 | 0.280 |
Why?
|
| Biomedical Research | 2 | 2014 | 806 | 0.280 |
Why?
|
| Medical Oncology | 1 | 2014 | 1423 | 0.270 |
Why?
|
| Carcinoma | 5 | 2019 | 2578 | 0.270 |
Why?
|
| Cell Proliferation | 11 | 2021 | 7226 | 0.260 |
Why?
|
| Mouth Mucosa | 2 | 2023 | 216 | 0.260 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 7 | 2022 | 476 | 0.250 |
Why?
|
| Tumor Microenvironment | 7 | 2024 | 2864 | 0.240 |
Why?
|
| DNA Damage | 6 | 2022 | 1954 | 0.240 |
Why?
|
| Biomarkers, Tumor | 11 | 2021 | 10331 | 0.240 |
Why?
|
| Sulfonamides | 1 | 2013 | 1823 | 0.240 |
Why?
|
| Ultraviolet Rays | 2 | 2024 | 575 | 0.230 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p18 | 3 | 2018 | 53 | 0.230 |
Why?
|
| Genes, p53 | 6 | 2022 | 1090 | 0.220 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2017 | 2488 | 0.220 |
Why?
|
| Phosphatidylinositol 3-Kinases | 3 | 2019 | 1678 | 0.220 |
Why?
|
| Calculi | 1 | 2022 | 14 | 0.210 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2022 | 133 | 0.210 |
Why?
|
| Checkpoint Kinase 1 | 3 | 2017 | 174 | 0.210 |
Why?
|
| Genomics | 7 | 2024 | 2738 | 0.210 |
Why?
|
| Apoptosis | 10 | 2022 | 7591 | 0.200 |
Why?
|
| Prognosis | 10 | 2023 | 21713 | 0.200 |
Why?
|
| CREB-Binding Protein | 1 | 2021 | 86 | 0.200 |
Why?
|
| Skin Neoplasms | 2 | 2016 | 4654 | 0.200 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2021 | 92 | 0.200 |
Why?
|
| MicroRNAs | 4 | 2020 | 2947 | 0.200 |
Why?
|
| Biomimetics | 1 | 2020 | 33 | 0.190 |
Why?
|
| Naltrexone | 1 | 2021 | 87 | 0.190 |
Why?
|
| Caspase Inhibitors | 1 | 2020 | 95 | 0.190 |
Why?
|
| Gain of Function Mutation | 1 | 2021 | 126 | 0.190 |
Why?
|
| Homologous Recombination | 1 | 2021 | 185 | 0.190 |
Why?
|
| Dipeptides | 1 | 2020 | 91 | 0.190 |
Why?
|
| Narcotic Antagonists | 1 | 2021 | 129 | 0.190 |
Why?
|
| Adrenergic Neurons | 1 | 2020 | 11 | 0.180 |
Why?
|
| LIM Domain Proteins | 2 | 2017 | 104 | 0.180 |
Why?
|
| S Phase | 2 | 2017 | 281 | 0.180 |
Why?
|
| Mitochondrial Proteins | 2 | 2020 | 369 | 0.180 |
Why?
|
| Disease Progression | 6 | 2020 | 6682 | 0.180 |
Why?
|
| Quinazolines | 2 | 2016 | 923 | 0.180 |
Why?
|
| Cisplatin | 3 | 2024 | 2432 | 0.180 |
Why?
|
| Histone Acetyltransferases | 1 | 2021 | 411 | 0.180 |
Why?
|
| F-Box-WD Repeat-Containing Protein 7 | 3 | 2017 | 83 | 0.180 |
Why?
|
| Male | 28 | 2023 | 123000 | 0.170 |
Why?
|
| Cell Transdifferentiation | 1 | 2020 | 112 | 0.170 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2018 | 2291 | 0.170 |
Why?
|
| Oncogenes | 2 | 2020 | 673 | 0.170 |
Why?
|
| NIMA-Related Kinases | 1 | 2018 | 11 | 0.170 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 5 | 2023 | 1331 | 0.170 |
Why?
|
| Penile Neoplasms | 1 | 2021 | 161 | 0.170 |
Why?
|
| Tumor Suppressor Proteins | 4 | 2022 | 1823 | 0.170 |
Why?
|
| Gene Expression | 5 | 2019 | 3570 | 0.170 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2014 | 1064 | 0.170 |
Why?
|
| Sensory Receptor Cells | 1 | 2020 | 141 | 0.160 |
Why?
|
| Proteomics | 3 | 2017 | 1380 | 0.160 |
Why?
|
| Mice, Nude | 7 | 2021 | 4307 | 0.160 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2020 | 278 | 0.160 |
Why?
|
| Transcription Factors, TFII | 1 | 2018 | 24 | 0.160 |
Why?
|
| Caspases | 1 | 2020 | 661 | 0.160 |
Why?
|
| Antineoplastic Agents | 6 | 2021 | 14289 | 0.160 |
Why?
|
| Female | 29 | 2022 | 141928 | 0.150 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2020 | 621 | 0.150 |
Why?
|
| Cellular Reprogramming | 1 | 2020 | 189 | 0.150 |
Why?
|
| Cytidine Deaminase | 1 | 2017 | 83 | 0.150 |
Why?
|
| Xenograft Model Antitumor Assays | 7 | 2021 | 3821 | 0.150 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2020 | 1265 | 0.150 |
Why?
|
| Databases, Genetic | 1 | 2020 | 745 | 0.150 |
Why?
|
| Checkpoint Kinase 2 | 2 | 2017 | 126 | 0.150 |
Why?
|
| Pyrazoles | 4 | 2020 | 1471 | 0.150 |
Why?
|
| Aurora Kinase A | 1 | 2018 | 202 | 0.150 |
Why?
|
| Pteridines | 1 | 2017 | 34 | 0.150 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2021 | 673 | 0.140 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2021 | 5178 | 0.140 |
Why?
|
| Keratosis, Actinic | 1 | 2016 | 37 | 0.140 |
Why?
|
| Thiophenes | 2 | 2017 | 148 | 0.140 |
Why?
|
| Disease-Free Survival | 3 | 2018 | 10001 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2017 | 249 | 0.140 |
Why?
|
| Neoplasm Proteins | 4 | 2018 | 3230 | 0.140 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2019 | 285 | 0.140 |
Why?
|
| CpG Islands | 2 | 2015 | 633 | 0.140 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2018 | 336 | 0.140 |
Why?
|
| Mice | 15 | 2021 | 34495 | 0.140 |
Why?
|
| Animals | 18 | 2021 | 59536 | 0.140 |
Why?
|
| Urea | 2 | 2017 | 290 | 0.140 |
Why?
|
| Malate Dehydrogenase | 1 | 2015 | 21 | 0.130 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2016 | 111 | 0.130 |
Why?
|
| Signal Transduction | 12 | 2022 | 11965 | 0.130 |
Why?
|
| Mitochondria | 2 | 2020 | 1282 | 0.130 |
Why?
|
| Molecular Targeted Therapy | 5 | 2021 | 2330 | 0.130 |
Why?
|
| Polymorphism, Genetic | 2 | 2018 | 1450 | 0.130 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 4 | 2020 | 521 | 0.130 |
Why?
|
| Hand Deformities, Congenital | 1 | 2015 | 87 | 0.130 |
Why?
|
| Indoles | 1 | 2020 | 1009 | 0.130 |
Why?
|
| Chromosome Duplication | 1 | 2015 | 157 | 0.130 |
Why?
|
| Hydroxamic Acids | 1 | 2017 | 442 | 0.120 |
Why?
|
| Dendritic Cells | 1 | 2021 | 1085 | 0.120 |
Why?
|
| B7-H1 Antigen | 2 | 2022 | 1022 | 0.120 |
Why?
|
| Cluster Analysis | 2 | 2014 | 1053 | 0.120 |
Why?
|
| Thymoma | 1 | 2018 | 246 | 0.120 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2019 | 1546 | 0.120 |
Why?
|
| Neoplasms, Squamous Cell | 2 | 2011 | 87 | 0.120 |
Why?
|
| Saliva | 1 | 2015 | 231 | 0.120 |
Why?
|
| Gene Silencing | 2 | 2014 | 837 | 0.120 |
Why?
|
| Phenotype | 4 | 2022 | 6295 | 0.120 |
Why?
|
| DNA Mutational Analysis | 3 | 2016 | 2283 | 0.120 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2022 | 1833 | 0.120 |
Why?
|
| Telomerase | 1 | 2017 | 525 | 0.120 |
Why?
|
| Personnel Selection | 1 | 2014 | 87 | 0.120 |
Why?
|
| Lung Neoplasms | 3 | 2023 | 11538 | 0.120 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2018 | 519 | 0.110 |
Why?
|
| ras Proteins | 2 | 2017 | 770 | 0.110 |
Why?
|
| Middle Aged | 17 | 2023 | 86204 | 0.110 |
Why?
|
| Anus Neoplasms | 1 | 2017 | 411 | 0.110 |
Why?
|
| Sequence Analysis, DNA | 3 | 2015 | 2483 | 0.110 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2017 | 661 | 0.110 |
Why?
|
| Thymus Neoplasms | 1 | 2018 | 400 | 0.110 |
Why?
|
| ErbB Receptors | 3 | 2020 | 2295 | 0.110 |
Why?
|
| Computational Biology | 2 | 2021 | 1271 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2015 | 641 | 0.110 |
Why?
|
| Cohort Studies | 4 | 2018 | 9244 | 0.110 |
Why?
|
| Gene Expression Profiling | 4 | 2018 | 5159 | 0.110 |
Why?
|
| Proteome | 1 | 2016 | 561 | 0.100 |
Why?
|
| Alleles | 1 | 2018 | 2437 | 0.100 |
Why?
|
| Pyrimidinones | 3 | 2020 | 314 | 0.100 |
Why?
|
| Papillomavirus E7 Proteins | 2 | 2022 | 64 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2013 | 15862 | 0.100 |
Why?
|
| Enzyme Inhibitors | 2 | 2017 | 1879 | 0.100 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 1249 | 0.100 |
Why?
|
| Cell Line | 2 | 2018 | 5114 | 0.100 |
Why?
|
| Colonic Polyps | 1 | 2013 | 209 | 0.100 |
Why?
|
| Neoplasm Transplantation | 3 | 2020 | 1519 | 0.100 |
Why?
|
| Neoplasms | 4 | 2024 | 15193 | 0.090 |
Why?
|
| Mutant Proteins | 1 | 2011 | 234 | 0.090 |
Why?
|
| Point Mutation | 1 | 2013 | 769 | 0.090 |
Why?
|
| Receptors, Notch | 1 | 2013 | 383 | 0.090 |
Why?
|
| Activins | 1 | 2009 | 98 | 0.090 |
Why?
|
| Cyclooxygenase 2 | 2 | 2009 | 483 | 0.090 |
Why?
|
| Proportional Hazards Models | 2 | 2015 | 4988 | 0.090 |
Why?
|
| Colon | 1 | 2013 | 670 | 0.090 |
Why?
|
| Tumor Burden | 3 | 2021 | 1987 | 0.090 |
Why?
|
| DNA-Binding Proteins | 3 | 2018 | 4821 | 0.090 |
Why?
|
| Cell Nucleus | 3 | 2023 | 1620 | 0.090 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 2 | 2021 | 76 | 0.090 |
Why?
|
| Patient-Specific Modeling | 2 | 2020 | 28 | 0.090 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2013 | 591 | 0.090 |
Why?
|
| Retinoblastoma Protein | 3 | 2022 | 335 | 0.090 |
Why?
|
| Proteins | 1 | 2017 | 1963 | 0.080 |
Why?
|
| Glutamine | 1 | 2011 | 299 | 0.080 |
Why?
|
| Exome | 1 | 2014 | 1239 | 0.080 |
Why?
|
| Protein Kinases | 1 | 2013 | 874 | 0.080 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2019 | 4757 | 0.080 |
Why?
|
| Adult | 11 | 2021 | 77950 | 0.080 |
Why?
|
| Aged | 12 | 2023 | 70117 | 0.080 |
Why?
|
| Transcription Factors | 2 | 2020 | 5270 | 0.080 |
Why?
|
| Lymphatic Metastasis | 1 | 2018 | 4844 | 0.080 |
Why?
|
| Schools, Medical | 1 | 2009 | 132 | 0.080 |
Why?
|
| Leukoplakia, Oral | 2 | 2023 | 70 | 0.080 |
Why?
|
| Epithelial-Mesenchymal Transition | 3 | 2021 | 973 | 0.080 |
Why?
|
| Pyrimidines | 2 | 2017 | 3518 | 0.080 |
Why?
|
| Immunotherapy | 1 | 2021 | 3341 | 0.080 |
Why?
|
| Taiwan | 2 | 2017 | 93 | 0.080 |
Why?
|
| Genome, Human | 1 | 2015 | 1869 | 0.070 |
Why?
|
| Lymph Nodes | 1 | 2018 | 2967 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 3 | 2021 | 3981 | 0.070 |
Why?
|
| Neoplasm Staging | 5 | 2021 | 13658 | 0.070 |
Why?
|
| Physicians | 1 | 2014 | 882 | 0.070 |
Why?
|
| Receptor, ErbB-2 | 1 | 2016 | 2518 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 3 | 2021 | 6942 | 0.070 |
Why?
|
| Mice, Inbred BALB C | 2 | 2021 | 2314 | 0.070 |
Why?
|
| Phosphorylation | 4 | 2018 | 4804 | 0.070 |
Why?
|
| Case-Control Studies | 3 | 2021 | 6100 | 0.070 |
Why?
|
| Colonic Neoplasms | 1 | 2013 | 1390 | 0.070 |
Why?
|
| DNA, Viral | 2 | 2022 | 694 | 0.060 |
Why?
|
| Phosphoproteins | 1 | 2011 | 1152 | 0.060 |
Why?
|
| Fellowships and Scholarships | 1 | 2009 | 390 | 0.060 |
Why?
|
| Aged, 80 and over | 6 | 2021 | 29902 | 0.060 |
Why?
|
| HIV Infections | 1 | 2017 | 2134 | 0.060 |
Why?
|
| Down-Regulation | 3 | 2015 | 2074 | 0.060 |
Why?
|
| Age Factors | 1 | 2014 | 5377 | 0.060 |
Why?
|
| Glucose | 1 | 2011 | 1248 | 0.060 |
Why?
|
| Sequence Deletion | 2 | 2017 | 875 | 0.060 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2005 | 215 | 0.060 |
Why?
|
| Gene Knockdown Techniques | 2 | 2019 | 1077 | 0.060 |
Why?
|
| Piperazines | 1 | 2013 | 2101 | 0.060 |
Why?
|
| Nucleotidyltransferases | 1 | 2024 | 82 | 0.060 |
Why?
|
| RNA, Messenger | 3 | 2022 | 6150 | 0.060 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2005 | 334 | 0.060 |
Why?
|
| Retrospective Studies | 4 | 2020 | 37905 | 0.060 |
Why?
|
| Curriculum | 1 | 2009 | 860 | 0.060 |
Why?
|
| DNA Replication | 2 | 2017 | 744 | 0.060 |
Why?
|
| Genetic Association Studies | 2 | 2020 | 1084 | 0.060 |
Why?
|
| ATPases Associated with Diverse Cellular Activities | 1 | 2022 | 85 | 0.050 |
Why?
|
| Fusobacterium | 1 | 2022 | 11 | 0.050 |
Why?
|
| Breast | 2 | 2006 | 1344 | 0.050 |
Why?
|
| Chromosomal Instability | 1 | 2024 | 233 | 0.050 |
Why?
|
| Aurora Kinases | 1 | 2022 | 189 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2017 | 6207 | 0.050 |
Why?
|
| Interferons | 1 | 2024 | 291 | 0.050 |
Why?
|
| Ubiquitin-Specific Peptidase 7 | 1 | 2022 | 40 | 0.050 |
Why?
|
| Genetic Fitness | 1 | 2022 | 39 | 0.050 |
Why?
|
| Cellular Senescence | 2 | 2015 | 382 | 0.050 |
Why?
|
| Conjunctiva | 1 | 2024 | 250 | 0.050 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2005 | 703 | 0.050 |
Why?
|
| Nuclear Proteins | 3 | 2017 | 3343 | 0.050 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 2021 | 67 | 0.050 |
Why?
|
| Radiobiology | 1 | 2021 | 56 | 0.050 |
Why?
|
| Genotype | 2 | 2022 | 4109 | 0.050 |
Why?
|
| Blotting, Western | 3 | 2014 | 3536 | 0.050 |
Why?
|
| Survival Analysis | 3 | 2020 | 9180 | 0.050 |
Why?
|
| Selection, Genetic | 1 | 2022 | 189 | 0.050 |
Why?
|
| Optical Imaging | 1 | 2022 | 157 | 0.050 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2021 | 57 | 0.050 |
Why?
|
| Epithelial Cells | 2 | 2006 | 1818 | 0.050 |
Why?
|
| Hyperplasia | 1 | 2022 | 557 | 0.050 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2021 | 80 | 0.050 |
Why?
|
| Deoxyglucose | 2 | 2011 | 115 | 0.050 |
Why?
|
| Cell Communication | 1 | 2023 | 509 | 0.050 |
Why?
|
| Gene Dosage | 2 | 2016 | 829 | 0.050 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2021 | 105 | 0.050 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2021 | 69 | 0.050 |
Why?
|
| TNF Receptor-Associated Factor 3 | 1 | 2020 | 22 | 0.050 |
Why?
|
| Biological Evolution | 1 | 2022 | 278 | 0.050 |
Why?
|
| Tobacco Use | 1 | 2020 | 54 | 0.050 |
Why?
|
| Adrenergic Antagonists | 1 | 2020 | 19 | 0.050 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 14889 | 0.050 |
Why?
|
| Acetylation | 1 | 2021 | 508 | 0.050 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2022 | 490 | 0.050 |
Why?
|
| Transfection | 2 | 2017 | 2944 | 0.050 |
Why?
|
| Protein Domains | 1 | 2021 | 314 | 0.050 |
Why?
|
| Receptors, Adrenergic | 1 | 2020 | 46 | 0.050 |
Why?
|
| Adenosine Triphosphatases | 1 | 2022 | 435 | 0.050 |
Why?
|
| Lymphocyte Depletion | 1 | 2021 | 264 | 0.050 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2005 | 674 | 0.050 |
Why?
|
| Disease Models, Animal | 3 | 2020 | 7222 | 0.050 |
Why?
|
| Ubiquitin | 1 | 2022 | 344 | 0.050 |
Why?
|
| Neurites | 1 | 2020 | 63 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2019 | 4938 | 0.040 |
Why?
|
| Nerve Fibers | 1 | 2020 | 106 | 0.040 |
Why?
|
| Bronchi | 1 | 2021 | 326 | 0.040 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2017 | 1756 | 0.040 |
Why?
|
| Feedback, Physiological | 1 | 2020 | 193 | 0.040 |
Why?
|
| Metformin | 2 | 2015 | 378 | 0.040 |
Why?
|
| Enzyme Activation | 2 | 2017 | 1764 | 0.040 |
Why?
|
| Cell Cycle | 2 | 2018 | 2084 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2012 | 5539 | 0.040 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2020 | 518 | 0.040 |
Why?
|
| Carcinogenesis | 2 | 2016 | 1026 | 0.040 |
Why?
|
| Breast Neoplasms | 3 | 2009 | 15694 | 0.040 |
Why?
|
| PubMed | 1 | 2018 | 41 | 0.040 |
Why?
|
| BRCA1 Protein | 1 | 2021 | 493 | 0.040 |
Why?
|
| Reactive Oxygen Species | 2 | 2015 | 987 | 0.040 |
Why?
|
| Combined Modality Therapy | 2 | 2021 | 8865 | 0.040 |
Why?
|
| Age of Onset | 1 | 2020 | 827 | 0.040 |
Why?
|
| Loss of Function Mutation | 1 | 2019 | 132 | 0.040 |
Why?
|
| Indazoles | 1 | 2020 | 297 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 538 | 0.040 |
Why?
|
| Receptor, Notch2 | 1 | 2017 | 25 | 0.040 |
Why?
|
| HCT116 Cells | 1 | 2018 | 348 | 0.040 |
Why?
|
| Models, Genetic | 1 | 2022 | 1113 | 0.040 |
Why?
|
| Natural Language Processing | 1 | 2018 | 119 | 0.040 |
Why?
|
| Kelch-Like ECH-Associated Protein 1 | 1 | 2017 | 104 | 0.040 |
Why?
|
| HLA-A Antigens | 1 | 2017 | 102 | 0.040 |
Why?
|
| Mice, Hairless | 1 | 2016 | 55 | 0.040 |
Why?
|
| NF-kappa B | 1 | 2024 | 1549 | 0.040 |
Why?
|
| Pharmacogenetics | 1 | 2018 | 260 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2018 | 700 | 0.040 |
Why?
|
| Gene Editing | 1 | 2019 | 216 | 0.040 |
Why?
|
| Young Adult | 3 | 2020 | 21445 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2018 | 503 | 0.040 |
Why?
|
| RNA, Neoplasm | 1 | 2019 | 771 | 0.040 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2017 | 229 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2021 | 1742 | 0.030 |
Why?
|
| Transcription, Genetic | 2 | 2020 | 3154 | 0.030 |
Why?
|
| Induction Chemotherapy | 1 | 2019 | 669 | 0.030 |
Why?
|
| Smad4 Protein | 1 | 2017 | 196 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2019 | 323 | 0.030 |
Why?
|
| Cell Division | 1 | 2020 | 2489 | 0.030 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2020 | 479 | 0.030 |
Why?
|
| Alu Elements | 1 | 2015 | 88 | 0.030 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2017 | 249 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 2017 | 1037 | 0.030 |
Why?
|
| DNA | 1 | 2024 | 2693 | 0.030 |
Why?
|
| Cyclin D1 | 1 | 2017 | 576 | 0.030 |
Why?
|
| Disease Management | 1 | 2021 | 1052 | 0.030 |
Why?
|
| 14-3-3 Proteins | 1 | 2015 | 143 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2013 | 7789 | 0.030 |
Why?
|
| Radiation, Ionizing | 1 | 2015 | 187 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2017 | 980 | 0.030 |
Why?
|
| Piperidines | 1 | 2020 | 1035 | 0.030 |
Why?
|
| PAX5 Transcription Factor | 1 | 2014 | 45 | 0.030 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2017 | 461 | 0.030 |
Why?
|
| Cadherins | 1 | 2017 | 660 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2011 | 2508 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2018 | 1489 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2017 | 1313 | 0.030 |
Why?
|
| Treatment Outcome | 4 | 2019 | 32848 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2015 | 528 | 0.030 |
Why?
|
| Paired Box Transcription Factors | 1 | 2014 | 134 | 0.030 |
Why?
|
| Sequence Alignment | 1 | 2015 | 844 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2022 | 2022 | 0.030 |
Why?
|
| Cell Movement | 1 | 2021 | 2466 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2015 | 481 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 2021 | 1664 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2017 | 1217 | 0.030 |
Why?
|
| Cell Growth Processes | 1 | 2013 | 342 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2016 | 651 | 0.030 |
Why?
|
| Benzamides | 1 | 2018 | 1832 | 0.030 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2014 | 388 | 0.030 |
Why?
|
| RNA Interference | 1 | 2017 | 1408 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2017 | 1046 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2017 | 992 | 0.030 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2015 | 622 | 0.030 |
Why?
|
| Bile Acids and Salts | 1 | 2013 | 246 | 0.030 |
Why?
|
| Pedigree | 1 | 2015 | 1890 | 0.030 |
Why?
|
| Cesium Radioisotopes | 1 | 2011 | 39 | 0.030 |
Why?
|
| Genetic Heterogeneity | 1 | 2013 | 318 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2021 | 5710 | 0.020 |
Why?
|
| INDEL Mutation | 1 | 2011 | 112 | 0.020 |
Why?
|
| Mitosis | 1 | 2013 | 615 | 0.020 |
Why?
|
| Codon, Nonsense | 1 | 2011 | 164 | 0.020 |
Why?
|
| Skin | 1 | 2016 | 1259 | 0.020 |
Why?
|
| Keratinocytes | 1 | 2011 | 241 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2017 | 5395 | 0.020 |
Why?
|
| Telomeric Repeat Binding Protein 2 | 1 | 2009 | 25 | 0.020 |
Why?
|
| Lung | 1 | 2021 | 3151 | 0.020 |
Why?
|
| Mucous Membrane | 1 | 2011 | 271 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2011 | 401 | 0.020 |
Why?
|
| Microsatellite Repeats | 1 | 2011 | 575 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 4744 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2011 | 342 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2015 | 1910 | 0.020 |
Why?
|
| Immunohistochemistry | 2 | 2011 | 7548 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2011 | 1082 | 0.020 |
Why?
|
| Binding Sites | 1 | 2013 | 2171 | 0.020 |
Why?
|
| Lactic Acid | 1 | 2011 | 305 | 0.020 |
Why?
|
| Base Sequence | 1 | 2015 | 4917 | 0.020 |
Why?
|
| Prevalence | 1 | 2017 | 3260 | 0.020 |
Why?
|
| Protein Kinase C | 1 | 2011 | 396 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 2011 | 571 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2011 | 598 | 0.020 |
Why?
|
| Glycolysis | 1 | 2011 | 519 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 6089 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2011 | 702 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2011 | 501 | 0.020 |
Why?
|
| Adolescent | 2 | 2019 | 31252 | 0.020 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2009 | 430 | 0.020 |
Why?
|
| Exons | 1 | 2011 | 1328 | 0.020 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2011 | 421 | 0.020 |
Why?
|
| Metabolomics | 1 | 2011 | 478 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2017 | 5112 | 0.020 |
Why?
|
| Cell Survival | 1 | 2013 | 3045 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2011 | 586 | 0.020 |
Why?
|
| Biomarkers | 1 | 2018 | 5047 | 0.020 |
Why?
|
| Genes, p16 | 1 | 2006 | 125 | 0.020 |
Why?
|
| Telomere | 1 | 2009 | 505 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 1489 | 0.020 |
Why?
|
| Survival Rate | 1 | 2020 | 12221 | 0.020 |
Why?
|
| Transcriptome | 1 | 2015 | 1859 | 0.020 |
Why?
|
| Carcinoma in Situ | 1 | 2009 | 487 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2013 | 2054 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2011 | 1152 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 4971 | 0.020 |
Why?
|
| Prostaglandins | 1 | 2005 | 77 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 10035 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 6869 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 4549 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 3639 | 0.010 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2009 | 1216 | 0.010 |
Why?
|
| Time Factors | 1 | 2017 | 12926 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2005 | 652 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2011 | 6009 | 0.010 |
Why?
|
| Thyroid Neoplasms | 1 | 2011 | 1866 | 0.010 |
Why?
|
| Risk Factors | 1 | 2017 | 17523 | 0.010 |
Why?
|
| Infant | 1 | 2015 | 13310 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2006 | 5637 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2005 | 2819 | 0.010 |
Why?
|